BRII-B Executes HKD 26,617 Share Buyback, Treasury Stock Rises to 13.59 Million

Bulletin Express10-20

Brii Biosciences Limited (BRII-B) disclosed that on 20 October 2026 it repurchased 30,000 ordinary shares on the Hong Kong Stock Exchange under its existing mandate dated 16 June 2026.

The shares were acquired at prices ranging from HKD 0.885 to HKD 0.89, translating into a volume-weighted average cost of HKD 0.8873 per share and an aggregate outlay of HKD 26,617.50.

Following the transaction, total treasury shares increased to 13.59 million, while issued shares outstanding (excluding treasury shares) declined marginally to 721.73 million. The company’s total issued share capital remains unchanged at 735.32 million shares.

Since receiving shareholder approval, BRII-B has repurchased 871,000 shares, representing 0.12% of the issued share count as of the mandate date. In accordance with Hong Kong listing rules, the company is subject to a moratorium on new share issues or treasury-share sales until 19 November 2026.

The board confirmed that the buyback complied with Main Board Rule 10.06 and that no material changes have been made to the explanatory statement filed on 24 April 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment